Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million
25 avr. 2024 07h00 HE
|
Optinose, Inc.
YARDLEY, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose to Present at the Needham Virtual Healthcare Conference
04 avr. 2024 16h01 HE
|
Optinose, Inc.
YARDLEY, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
15 mars 2024 15h34 HE
|
Optinose, Inc.
ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps Clinical...
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
07 mars 2024 07h00 HE
|
Optinose, Inc.
PDUFA target action date is March 16, 2024, for the Company's sNDA. If approved, the Company is prepared for launch of XHANCE for treatment of patients diagnosed with chronic sinusitis Physicians...
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results
29 févr. 2024 16h40 HE
|
Optinose, Inc.
YARDLEY, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice
18 janv. 2024 12h00 HE
|
Optinose, Inc.
XHANCE significantly reduced both symptoms and sinus opacification in participants with chronic sinusitis (chronic rhinosinusitis) in two randomized controlled Phase 3 Clinical Trials (ReOpen1 and...
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
06 déc. 2023 07h00 HE
|
Optinose, Inc.
The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis ...
Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference
22 nov. 2023 09h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports Third Quarter 2023 Financial Results and Operational Updates
09 nov. 2023 07h00 HE
|
Optinose, Inc.
Company reports third quarter 2023 XHANCE net revenue of $19.8 million and increases full year 2023 XHANCE net revenue guidance Strong improvement in operating efficiency as SG&A and R&D...
Optinose Announces Reporting Date for Third Quarter 2023 Financial Results
27 oct. 2023 08h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...